Hemostasis

Precision BioLogic's Chromogenic FIX Assay FDA-Cleared for Sale in U.S.

Retrieved on: 
Thursday, January 5, 2023
Factor IX, Medicine, NS, Defence Scientific Advisory Council, Hemostasis, Biologic, Medical laboratory, NHF, Plasma, Half-life, FIX, Mayo Clinic, Haemophilia, FDA, Diagnosis, Medical device, Pharmaceutical industry, EU

The latest in Precision BioLogic's family of hemophilia-related diagnostic products, CRYOcheck Chromogenic Factor IX is intended for use by clinical labs to identify factor IX (FIX) deficiency in human plasma and aid in the management of hemophilia B.

Key Points: 
  • The latest in Precision BioLogic's family of hemophilia-related diagnostic products, CRYOcheck Chromogenic Factor IX is intended for use by clinical labs to identify factor IX (FIX) deficiency in human plasma and aid in the management of hemophilia B.
  • It is the only FDA-cleared chromogenic FIX assay on the market and answers a growing demand for such tests.
  • "Recognizing the need for FDA-cleared chromogenic assays, Precision BioLogic developed CRYOcheck Chromogenic Factor IX to meet the needs of today's clinical laboratories.
  • It is Precision BioLogic's second hemophilia-related chromogenic assay.

In Vitro Diagnostics Market worth $144.7 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, January 5, 2023
Government, Cancer, Nephrology, POC, HIV/AIDS, Cardiology, Urine test strip, Microbiology, Hemostasis, Growth, Patient, Infection, Degenerative disease, IVD, Physician, Hematology, Data management, Diabetes, Prevalence, Medical device, Healthcare

The high growth in this market is attributed to the technological advancements in diagnostic analyzers.

Key Points: 
  • The high growth in this market is attributed to the technological advancements in diagnostic analyzers.
  • Market players are focused on innovating and launching IVD analyzers with inbuilt software and technology that aids in faster diagnostic results.
  • Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies.
  • The growth in this market is attributed to the increasing adoption of point-of-care (POC) testing for hematology diagnostics.

In Vitro Diagnostics Market worth $144.7 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, January 5, 2023
Government, Cancer, Nephrology, POC, HIV/AIDS, Cardiology, Urine test strip, Microbiology, Hemostasis, Growth, Patient, Infection, Degenerative disease, IVD, Physician, Hematology, Data management, Diabetes, Prevalence, Medical device, Healthcare

The high growth in this market is attributed to the technological advancements in diagnostic analyzers.

Key Points: 
  • The high growth in this market is attributed to the technological advancements in diagnostic analyzers.
  • Market players are focused on innovating and launching IVD analyzers with inbuilt software and technology that aids in faster diagnostic results.
  • Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies.
  • The growth in this market is attributed to the increasing adoption of point-of-care (POC) testing for hematology diagnostics.

Werfen Receives 2022 IMV ServiceTrak Awards for Best Customer Satisfaction and Best Service in Hemostasis and Blood Gas

Retrieved on: 
Wednesday, January 4, 2023
Hemostasis, Original equipment manufacturer, GEM, CO-oximeter, ACL, NOVA, Chrysler, Strategic planning, Autoloader, Name, ACD, Blood, Catheter, Patent, Automation, Thrombosis, Agilent ChemStation, IBM Aptiva, Originality, Data management, Hospital, High-dependency unit, Health care, Accreditation, Coagulopathy, Information technology, OEM, Commercial Operating System (COS), POC, IMV, Pharmaceutical industry, Medical device, Medical imaging, Science, Autoimmunity, Werfen, Coagulation

BEDFORD, Mass., Jan. 4, 2023 /PRNewswire/ -- Werfen today announced that it has received five 2022 IMV ServiceTrak Awards including Best System Performance and Best Service in the Coagulation (Hemostasis) category, as well as Best Customer Satisfaction, Best System Performance and Best Service in the Blood Gas category.

Key Points: 
  • BEDFORD, Mass., Jan. 4, 2023 /PRNewswire/ -- Werfen today announced that it has received five 2022 IMV ServiceTrak Awards including Best System Performance and Best Service in the Coagulation (Hemostasis) category, as well as Best Customer Satisfaction, Best System Performance and Best Service in the Blood Gas category.
  • IMV ServiceTrak 2022 Clinical Laboratory Awards are presented to manufacturers whose customers are highly satisfied with their products and services.
  • Results are based on interviews conducted with respondents in 1,716 clinical testing locations in the US, representing 2,169 instruments.
  • "It's an incredible honor to have the quality of our products and customer service, in both our Hemostasis and Acute Care Diagnostics business lines, recognized among the winners of the 2022 IMV awards," said Bill Crandell, Vice President of Commercial Operations, North America at Werfen.

Surgical Sealants, Adhesives and Hemostats Global Market - Forecast to 2029

Retrieved on: 
Thursday, December 22, 2022
Merck KGaA v. Integra Lifesciences I, Ltd., Johnson & Johnson, General surgery, Gel, SAH, Adhesive, Ethicon Inc., Baxter International, Medtronic, Bleeding, Urology, Hospital, Health, Ageing, Infection, Geography, Fibrin, Speciality chemicals, Hemostasis, Orthopedic surgery, Pulmonology, Others, Gynaecology, Teleflex, CryoLife, Neurosurgery

View original content:https://www.prnewswire.com/news-releases/surgical-sealants-adhesives-and...

Key Points: 
  • According to IQ4I analysis, the SAH global market is expected to grow at mid-single digit CAGR from 2022 to 2029 to reach $4,366.0 million by 2029.
  • The SAH global market is mainly segmented based on products, applications, end-users, and based on geography.
  • Among these, the hemostat accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029.
  • Hemostats are classified based on function into mechanical hemostats, active hemostats, flowable hemostats, and fibrin sealants hemostats, among them, the mechanical hemostats accounted for the largest revenue in 2022 and are expected to grow at mid-single digit CAGR from 2022 to 2029.

Tricol Biomedical Expands Product Lines with Group Purchasing Organizations Premier and Vizient; Salvin Dental Specialties Is Now Tricol’s Exclusive U.S. Dental Distributor

Retrieved on: 
Tuesday, December 13, 2022
GPO, Army of the United States, Hemostasis, Partnership, Premier, Inc., Bleeding, Hospital, Thibault Tricole, OR, Pain, Injury, Trauma, Research, Death, Patient, Dentistry, Vizient, Inc.

In addition, the company has developed an exclusive U.S. distribution agreement with Salvin Dental Specialties for the company’s HemCon® Dental Dressing PRO product line.

Key Points: 
  • In addition, the company has developed an exclusive U.S. distribution agreement with Salvin Dental Specialties for the company’s HemCon® Dental Dressing PRO product line.
  • The company has added new hemostatic devices to its contracts with Premier and Vizient.
  • Both serve as hospital purchasing partners within the United States for their procedural care product lines.
  • “At Tricol, it’s all about access to our products — whether online, through our direct sales entities, or through our distribution partnerships.

Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia

Retrieved on: 
Saturday, December 10, 2022
Haemophilia A, Hemostasis, Bleeding, Protein, Disorder, Annual report, Person, FDA, DRS, Omicron, Safety, Arthropathy, Maintenance, Coagulation, Pharmacokinetics, Factor VIII, Haemophilia, ASH, Hemarthrosis, Thrombin, Doctor of Philosophy, APC, VIII, Joint, Factor IX, PWH, Research, OLE, Risk, Male, COVID-19, Volunteering, Patient, Coagulopathy, Pharmaceutical industry, Delta

The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors).

Key Points: 
  • The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors).
  • Yver and Baglin share the OLE data slides presented at ASH and discuss the SerpinPC registrational program within a recorded webcast now available on the Company’s website at https://investors.centessa.com/events-presentations .
  • SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.
  • Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients.

Aronora CEO Named National Academy of Inventors Fellow

Retrieved on: 
Thursday, December 8, 2022
OHSU, Thrombosis, TPA, Oregon Health & Science University, National academy, Hemostasis, Bleeding, Quality of life, Prevalence, Fellows, FDA, School, NAI, University, Economic development, Death, Coagulation, Stroke, Experiment, Doctor of Philosophy, Innovation, Medical school, National Academies of Sciences, Engineering, and Medicine, Biomedicine, Research, Heparin, Biomedical engineering, Therapy, National Academy of Inventors, Pharmaceutical industry, Science, Invention, Medicine, Engineering

PORTLAND, Ore., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Erik Tucker, Ph.D., joins an elite group of inventors with his election to the National Academy of Inventors.

Key Points: 
  • PORTLAND, Ore., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Erik Tucker, Ph.D., joins an elite group of inventors with his election to the National Academy of Inventors.
  • "I am truly honored to be elected as a Fellow of the National Academy of Inventors, and proud to join an exceptional group of distinguished Fellows worldwide," said Tucker.
  • The National Academy of Inventors Fellows Program recognizes inventors who have demonstrated prolific innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society.
  • Election as an NAI Fellow is the highest professional distinction accorded to academic inventors.

The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound System

Retrieved on: 
Monday, December 5, 2022
Centers for Medicare & Medicaid Services, Wound healing, Level 2, Hemostasis, Food and Drug Administration Amendments Act of 2007, Mouth ulcer, Food, FDA, News, Biotechnology, Healthcare Common Procedure Coding System, Center for Medicare and Medicaid Innovation, Risk, Drug Quality and Security Act, Medicare, Patient, HCPCS, OTCQB, AC5, Trauma, Therapy, Skin, Arch, Pharmaceutical industry

The preliminary recommendation was discussed at CMS’ First Biannual 2022 HCPCS Public Meeting, which was held on November 30, 2022.

Key Points: 
  • The preliminary recommendation was discussed at CMS’ First Biannual 2022 HCPCS Public Meeting, which was held on November 30, 2022.
  • The HCPCS code would better enable providers to bill third party payors for AC5 that is used in doctors’ offices.
  • AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing.
  • Arch has received regulatory clearance to market AC5® Advanced Wound System in the United States and AC5® Topical Hemostat in Europe.

Olympus Announces EMEA Expansion of Exclusive Partnership with EndoClot Plus, Inc.

Retrieved on: 
Thursday, December 8, 2022
Polyp, Physician, Medicine, Endoscopic mucosal resection, Partnership, Patient, Hemostasis, Adenoma, Laparoscopy, ESD, Endoscopy, Olympus, Quality of life, News, Multimedia, Safety, EPI, EMR, Pharmaceutical industry, Medical device, GI

WESTBOROUGH, Mass., Dec. 8, 2022 /PRNewswire/ -- Olympus, a global medical technology company focused on designing and delivering innovative solutions for medical and surgical procedures, announced today a new exclusive distribution agreement with EndoClot® Plus, Inc. (EPI) that extends our strategic partnership to the Europe, Middle East and Africa (EMEA) region. This news follows a successful commercialization of the EndoClot product portfolio in the United States, announced in April 2022.

Key Points: 
  • This news follows a successful commercialization of the EndoClot product portfolio in the United States, announced in April 2022.
  • EPI technologies complement Olympus' comprehensive portfolios in GI (gastrointestinal) endoscopy and the company's overall medtech strategy.
  • "We are very excited to expand our global partnership with Olympus," said Stephen Heniges, President, EPI.
  • "With Olympus' support in the U.S. and now EMEA, we expect that more healthcare providers and their patients will be able to benefit from our solutions.